Abstract
BackgroundWe present here our novel macrophage-directed CEAxCD47 bispecific antibody (bsAb) NILK-2401 alone and in combination with the CEAxCD3 T-cell retargeting bsAb NILK-2301 for multimodal treatment of CEA-expressing solid malignancies, e.g.,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
